insights_auto
Kāpēc uzņēmuma ALNOV akciju cena ir pieaugusi 4,65%?
Atklājiet vairāk iespējuchevron_right
ALNOV:EPA
Novacyt SA
0,45 €
arrow_upward
+4,65%(+0,020) 1 d.
13. nov., 17:35:28 GMT+1 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: ALNOV…
Atvērt
0,44 €
Augsta
0,46 €
Zema
0,43 €
Tirgus kapitalizācija
30,13 milj.
Vid. apjoms
164,75 tūkst.
Apjoms
156,80 tūkst.
Augstākā 52 ned.
1,04 €
Zemākā 52 ned.
0,29 €
Peļņa uz vienu akciju
-0,38 €
Apgrozībā esošās akcijas
72,59 milj.
Darbinieku skaits
228
Atvērt
0,44 €
Augsta
0,46 €
Zema
0,43 €
Tirgus kapitalizācija
30,13 milj.
Vid. apjoms
164,75 tūkst.
Apjoms
156,80 tūkst.
Augstākā 52 ned.
1,04 €
Zemākā 52 ned.
0,29 €
Peļņa uz vienu akciju
-0,38 €
Apgrozībā esošās akcijas
72,59 milj.
Darbinieku skaits
228
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
TradingKey
·
pirms 10 stundām
S&P 500 Forecast: Index Poised to Retest Record High in November After 500-Point Pullback, Biggest Daily Gain in Nearly Seven Months
The Motley Fool
·
pirms 21 stundas
Prediction: This Small-Cap Value ETF Will Beat the S&P 500 Over the Next 10 Years
TradingView
·
pirms 17 stundām
EXCLUSIVE: S&P 500’s Sell-Off Tested Buffered ETFs: Expert Explains Why a 10% Buffer May Not Protect You as Expected
Traders Union
·
pirms 2 stundām
Quinten Francois: Bitcoin and Ethereum underperform S&P 500 over five years
Profils
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Par “Novacyt SA”
ĢenerāldirektorsDavid Allmond
Darbinieki228
Dibināšanas datums2006. gada 3. jūl.
Galvenais birojs-
SektorsHealth Care
Nozare-
Tīmekļa vietnenovacyt.com